Role of Aldosterone Blockade in Heart Failure

Heart Failure Clinics

Volumn 1, Issue 1, 2005, Pages 49-56

  Pitt, Bertram ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; GLYCERYL TRINITRATE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MINERALOCORTICOID RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT; POTASSIUM; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SPIRONOLACTONE;

ADRENAL GLAND; CLINICAL FEATURE; CLINICAL TRIAL; COLLAGEN SYNTHESIS; COST EFFECTIVENESS ANALYSIS; DEFIBRILLATOR; DIABETES MELLITUS; DRUG FATALITY; DRUG MECHANISM; ENZYME ACTIVITY; FIBRINOLYSIS; GYNECOMASTIA; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART RATE VARIABILITY; HOSPITALIZATION; HUMAN; HYPOKALEMIA; IMPOTENCE; KIDNEY CLEARANCE; KNOCKOUT MOUSE; LIBIDO DISORDER; MASTALGIA; MENSTRUAL IRREGULARITY; MORTALITY; NONHUMAN; POTASSIUM BLOOD LEVEL; REVIEW; SUDDEN DEATH; THROMBOCYTE ACTIVATION; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; DRUG EVALUATION; HEART FAILURE; HEART FAILURE, CONGESTIVE; HUMANS; RECEPTORS, MINERALOCORTICOID; SYSTOLE; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33645967483     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2004.12.003     Document Type: Review

References (63)

1. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 316 (1987) 1429-1435
2. The SOLVD INVESTIGATORS. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 (1991) 293-302
3. CIBS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet 353 (1999) 9-13
4. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353 (1999) 2001-2007
5. Packer M., Coats A.J., Fowler M.B., et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344 (2001) 1651-1658
6. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341 (1999) 709-717
7. Pitt B., Remme W., Zannad F., et al., of the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 14 (2003) 1309-1321
8. van Vliet A.A., Donker A.J., Nauta J.J., et al. Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. Am J Cardiol 71 (1993) 21A-28A
9. MacFadyen R.J., Gorski J.C., Brater D.C., et al. Furosemide responsiveness non-adherence and resistance during the chronic treatment of heart failure: a longitudinal study. Br J Clin Pharmacol 57 (2004) 622-631
10. Muller J. Spironolactone in the management of congestive cardiac failure: a review. Clin Ther 9 (1986) 63-76
11. Funder J.W., Pearce P.T., Smith R., et al. Vascular type I aldosterone binding sites are physiological mineralocorticoid receptors. Endocrinology 125 (1989) 2224-2226
12. Lombes M., Oblin M.E., Gasc J.M., et al. Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circ Res 71 (1992) 503-510
13. Rajagopalan S., Duquaine D., King S., et al. Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 105 (2002) 2212-2216
14. Luft F.C. Mechanisms and cardiovascular damage in hypertension. Hypertension 37 (2001) 594-598
15. Leopold J.A., Scribner A.E., Dam A., et al. Aldosterone impairs vascular reactivity by decreasing glucose 6-phosphate dehydrogenase activity [abstract]. Circulation 2004;110:III-154
16. Mitchell B.M., Smith A.D., Webb R.C., et al. Aldosterone decreases endothelium-dependent relaxation by down-regulating GTP cyclohydrolase [abstract]. Hypertension 42 435 (2003) 161
17. Mazak I., Fiebler A., Dominik N., et al. Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells. Circulation 109 (2004) 2792-2800
18. Quinn S., and Williams G. Regulation of aldosterone secretion. Annu Rev Physiol 50 (1988) 409-426
19. Okubo S., Niimura F., Nishimura H., et al. Angiotensin-independent mechanism for aldosterone synthesis during chronic extracellular fluid volume depletion. J Clin Invest 99 5 (1997) 855-860
20. Pitt B. "Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin-converting enzyme inhibitors: implications for therapy. Cardiovasc Drugs Ther 99 (1995) 145-149
21. Blasi E.R., Frierdrich G.E., De Ciechi P.A., et al. Aldosterone/salt-induced myocardial injury: a vascular inflammatory disease. Amer J Hypertens 14 (2001) 8A-9A
22. Weber K.T. Fibrosis and hypertensive heart disease. Curr Opin Cardiol 25 (2000) 264-272
23. MacFadyen R.J., Barr C.S., and Struthers A.D. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cadiovasc Res 35 (1997) 30-34
24. Zannad F., Alla F., Dousset B., et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES). Circulation 102 (2000) 2700-2706
25. Benetos A., Lacolley P., and Safar M.E. Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol 17 (1997) 1152-1156
26. Brilla C.G., Pick R., Tan L.B., et al. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 67 (1990) 1355-1364
27. Iglarz M., Touyz R.M., Viel E.C., et al. Involvement of oxidative stress in the profibrotic action of aldosteone. Interaction with the renin-angiotension system. Am J Hypertens 17 (2004) 597-603
28. Suzuki G., Morita H., Mishima T., et al. Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation 106 (2002) 2967-2972
29. Susic D., Varagic J., Ahn I., et al. Eplerenone improves coronary hemodynamics and reduces cardiac fibrosis in aging spontaneously hypertensive rats [abstract]. J Am Coll Cardiol 43 (2004) 482A
30. LaColley P., Labat C., Pujol A., et al. Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats effects of eplerenone. Circulation 106 (2002) 2848-2853
31. Pitt B., Reichek N., Willenbrock R., et al. Effect of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy study. Circulation 108 (2003) 1831-1838
32. Qin W., Rudolph A.E., Bond B.R., et al. Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circ Res 93 (2003) 69-76
33. Lim P.O., Donnan P.T., and Struthers A.D. Exercise capacity and brain natruiretic peptide in hypertensin. J Cardiovasc Pharmacol 40 (2002) 519-527
34. Bauersachs J., Heck M., Fraccarollo D., et al. Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression. J Am Coll Cardiol 39 (2002) 351-358
35. Meyer B., Huelsmann M., Strecker K., et al. Flow-mediated vasodilation predicts outcome in patients with chronic heart failure. J Am Coll Cardiol 43 (2004) 198A
36. Brown N.J., Kim K.S., Chen Y.Q., et al. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab 85 (2000) 336-344
37. Schaefer A., Fraccarollo D., Hildemann S., et al. Inhibition of platelet activation in congestive heart failure by selective aldosterone receptor antagonism and angiotensin-converting enzyme inhibition [abstract]. Eur Heart J 23 Suppl (2002) 401
38. Barr C.S., Lang C.C., Hanson J., et al. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 76 17 (1995) 1259-1265
39. Kasama S., Toyama T., Kumakura H., et al. Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy. J Am Coll Cardiol 41 4 (2003) 574-581
40. Zhang Z.H., Francis J., Weiss R.M., et al. The rennin-angiotensin-aldosterone system excites hypothalmic paraventricular nucleus neurons in heart failure. Am J Physiol Heart Circ Physiol 283 (2002) H423-H433
41. Chowdhary S., Vaile J.C., Fletcher J., et al. Nitric oxide and cardiac autonomic control in humans. Hypertension 36 (2000) 264-269
42. Schwarz P., Diem R., Dun N.J., et al. Endogenous and exogenous nitric oxide inhibits norepinephrine release from rat heart sympathetic nerves. Circ Res 77 (1995) 841-848
43. Harada E., Yoshimura M., Yasue H., et al. Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes. Circulation 104 (2001) 137-139
44. Michel F., Ambroisine M.L., Duriez M., et al. Aldosterone enhances ischemia-induced neovascularization through angiotensin II-dependent pathway. Circulation 109 (2004) 1933-1937
45. Yamamuro M., Yoshimura M., Nakayama M. Aldosterone reduces gene expression of angiotensin-converting enzyme 2 in rat neonatal cardiomyocytes. Circulation 2004;110:III-635
46. Kobayashi N., Honda T., Hara K., et al. Eplerenone shows renoprotective effects by reducing LOX-1 mediated adhesion molecule expression and PK cepsilon-MAP kinase -p90 RSK pathway activation. [abstract]. Hypertension 42 446 (2003) 216
47. Keridar S., Kaplan M., Pavlotsky E., et al. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzymes and the receptors for angiotensin II and aldosterone. Circulation 109 (2004) 2213-2220
48. Zhou Y., Chen R., and Hu L. Angiotensin II and aldosterone are both required to stimulate atheosclerosis in Apo-E deficient mice [abstract]. Hypertension 42 (2003) 403A
49. Swedberg K., Eneroth P., Kjekshus J., et al. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 82 (1990) 1730-1760
50. Hayashi M., Tsutamoto T., Wada A., et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 107 (2003) 2259-2265
51. Tsutamoto T., Wada A., Maeda K., et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol 37 (2001) 1228-1233
52. Cicoira M., Zanolla L., Rossi A., et al. Long-term, dose dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol 40 (2002) 304-310
53. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336 (1997) 525-533
54. Berry C., and McMurray J.J. Serious adverse events experienced by patients with chronic heart failure taking spironolactone. Heart 85 4 (2001) E8
55. Schepkens H., Vanholder R., Billiouw J.M., et al. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med 110 (2001) 438-441
56. Sveensson M., Gustafsson F., Galatius S., et al. Hyperkalaemia and impaired renal function in patients taking spironolactone for congestive heart failure. Retrospective study. Br Med J 327 (2003) 1141-1142
57. Wrenger E., Muller R., Moesenthin M., et al. Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers; analysis of 44 cases. Br Med J 327 (2003) 147-149
58. Juurlink D.N., Mamdani M.M., Lee D.S., et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351 (2004) 543-551
59. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
60. Hohnloser S.H., Kuck K.H., Dorian P., et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 351 (2004) 2481-2488
61. Moss A.J., Vyas A., Greenberg H., et al. Temporal aspects of improved survival with the implanted defibrillator (MADIT-II). Am J Cardiol 109 (2004) 2792-2800
62. Izawa H., Murase Y., Xu J.L., et al. Spironolactone improves left ventricular chamber stiffness and diastolic function associated with regression of myocardial fibrosis in asymptomatic patients with dilated cardiomyopathy [abstract]. Circulation 2004;110:III-479
63. Pfeffer M.A., McMurray J.J., Velazquez E.J., et al., for the Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction or both. N Engl J Med 349 (2003) 1893-1906